can tirzepatide affect birth control The impact of and glucagon-like peptide 1 receptor agonists on oral hormonal contraception Tirzepatide & Contraceptives: Side Effects

Description

Tirzepatide: A Dual-Action Approach to Weight Loss Tirzepatide is a dual receptor agonist, meaning it activates both GLP-1 and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors

7A) and DPP4 (Fig

Lai TW, Zhang S, Wang YT

NICE guidance on obesity management (CG189 and recent technology appraisals) recommends a stepwise approach: First-line: Lifestyle interventions including dietary modification, increased physical activity, and behavioural support Pharmacotherapy: Consider when BMI 35 kg/m (or 30 kg/m with comorbidities) and lifestyle measures have been insufficient Licensed options: Orlistat remains a primary pharmacological option in NHS formularies, with GLP-1 receptor agonists like semaglutide (Wegovy) now available through specialist services for those with BMI 35 kg/m (or 30 kg/m with comorbidities) and at least one weight-related comorbidity Bariatric surgery: Considered for those with BMI 40 kg/m (or 35 kg/m with comorbidities) when other measures have failed NICE guidance emphasises using licensed medications with established safety profiles and does not recommend combining weight loss drugs without robust evidence